Good news for Teva at last: generic to Lialda launched

Good news are coming from Teva at last: the Israeli-based pharmaceutical group has announced it has launched the generic version of Lialda (mesalamine) 1.2g in the US. Mesalamine is indicated for the treatment of ulcerative colitis, a disorder affecting over 1 million US citizens. The drug generated sales of approximately $1.11bn in 2017. Mesalamine joins Teva’s rich generics portfolio, which now includes approximately 600 generics.

(Source: Teva)